Currently approved ICIs in front-line and/or subsequent treatment lines for lung cancer include pembrolizumab, nivolumab, and cemiplimab that target programmed cell death-1 (PD-1); atezolizumab and durvalumab that target programmed cell death-1-ligand 1 (PD-L1); and ipilimumab and tremelimumab that target cytotoxic T-lymphocyte antigen 4 (CTLA-4) [59]. This evidence concerns the gene PDCD1 and lung carcinoma.